Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study compares PharmaJet’s Tropis intradermal, needle-free injection system against traditional needle and syringe intramuscular administration.
According to a news release, the study will be performed in collaboration with Padjadjaran University (UNPAD) in Indonesia. PharmaJet expects the study to recruit approximately 900 girls aged nine to 14 years old in early 2023. This follows PharmaJet’s preliminary studies evaluating intradermal delivery for HPV vaccines.
Get the full story at our sister site, Drug Delivery Business News.
